JP2023532675A5 - - Google Patents
Info
- Publication number
- JP2023532675A5 JP2023532675A5 JP2022580178A JP2022580178A JP2023532675A5 JP 2023532675 A5 JP2023532675 A5 JP 2023532675A5 JP 2022580178 A JP2022580178 A JP 2022580178A JP 2022580178 A JP2022580178 A JP 2022580178A JP 2023532675 A5 JP2023532675 A5 JP 2023532675A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- combination
- use according
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20182364.8 | 2020-06-25 | ||
| EP20182364 | 2020-06-25 | ||
| EP21167277 | 2021-04-07 | ||
| EP21167277.9 | 2021-04-07 | ||
| PCT/EP2021/067346 WO2021260109A1 (en) | 2020-06-25 | 2021-06-24 | A COMBINATION OF A CBP/p300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532675A JP2023532675A (ja) | 2023-07-31 |
| JP2023532675A5 true JP2023532675A5 (https=) | 2024-06-19 |
Family
ID=76502741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580178A Pending JP2023532675A (ja) | 2020-06-25 | 2021-06-24 | ＥＧＦＲ突然変異ＮＳＣＬＣの治療に使用するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＥＧＦＲ阻害剤の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230255966A1 (https=) |
| EP (1) | EP4171556A1 (https=) |
| JP (1) | JP2023532675A (https=) |
| KR (1) | KR20230028512A (https=) |
| CN (1) | CN115701996B (https=) |
| AU (1) | AU2021298153A1 (https=) |
| BR (1) | BR112022025911A2 (https=) |
| CA (1) | CA3183982A1 (https=) |
| IL (1) | IL299438A (https=) |
| MX (1) | MX2022016496A (https=) |
| WO (1) | WO2021260109A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4041399A1 (en) | 2019-10-02 | 2022-08-17 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| KR20230028798A (ko) | 2020-06-25 | 2023-03-02 | 톨레모 테라퓨틱스 아게 | 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물 |
| IL307402A (en) | 2021-04-07 | 2023-12-01 | Tolremo Therapeutics Ag | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer |
| WO2024130029A1 (en) * | 2022-12-15 | 2024-06-20 | Apollomics, Inc. | Treatment of cancer resistant to egfr tki using c-met inhibitor |
| PL449237A1 (pl) * | 2024-07-15 | 2026-01-19 | Uniwersytet Łódzki | Inhibitor acetylotransferaz do zastosowania w leczeniu niedrobnokomórkowego raka płuc oraz potrójnie negatywnego nowotworu piersi opornego na paklitaksel |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| WO2013148114A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| MX2016004570A (es) * | 2013-10-11 | 2016-09-08 | Genentech Inc | Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. |
| WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| CN109715790A (zh) | 2016-07-25 | 2019-05-03 | 埃皮兹姆公司 | Crebbp相关的癌症疗法 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| MY205552A (en) * | 2017-05-30 | 2024-10-25 | Deciphera Pharmaceuticals Inc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl ]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
| US20200155566A1 (en) * | 2017-08-03 | 2020-05-21 | Novartis Ag | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |
| KR20200036880A (ko) * | 2017-08-03 | 2020-04-07 | 노파르티스 아게 | 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물 |
| GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| CN110652514A (zh) * | 2018-06-29 | 2020-01-07 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制药用途 |
| US10870648B2 (en) | 2018-06-29 | 2020-12-22 | Forma Therapeutics, Inc. | Inhibiting CREB binding protein (CBP) |
| US12290521B2 (en) * | 2018-07-25 | 2025-05-06 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating BET inhibitor-resistant cancers |
-
2021
- 2021-06-24 BR BR112022025911A patent/BR112022025911A2/pt unknown
- 2021-06-24 EP EP21733158.6A patent/EP4171556A1/en active Pending
- 2021-06-24 JP JP2022580178A patent/JP2023532675A/ja active Pending
- 2021-06-24 CN CN202180044594.4A patent/CN115701996B/zh active Active
- 2021-06-24 WO PCT/EP2021/067346 patent/WO2021260109A1/en not_active Ceased
- 2021-06-24 KR KR1020237002916A patent/KR20230028512A/ko active Pending
- 2021-06-24 AU AU2021298153A patent/AU2021298153A1/en active Pending
- 2021-06-24 MX MX2022016496A patent/MX2022016496A/es unknown
- 2021-06-24 CA CA3183982A patent/CA3183982A1/en active Pending
- 2021-06-24 IL IL299438A patent/IL299438A/en unknown
- 2021-06-24 US US18/012,278 patent/US20230255966A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532675A5 (https=) | ||
| JP2024133475A5 (https=) | ||
| TW202038957A (zh) | 抗體-藥物結合物與激酶抑制劑之組合 | |
| JP2023533464A5 (https=) | ||
| JP2020504742A5 (https=) | ||
| JP7123806B2 (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| JP2018504416A5 (https=) | ||
| JP2025038167A (ja) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| RU2020108191A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибиторa циклин-d-киназы | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| RU2020108192A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf | |
| CA2439440A1 (en) | Treatment of tuberous sclerosis associated neoplasms | |
| WO2021224867A1 (en) | Pharmaceutical combination comprising tno155 and nazartinib | |
| JP2023524789A5 (https=) | ||
| JP2019514864A (ja) | 肝癌の治療方法 | |
| CN113543784A (zh) | 用于治疗或预防癌症的喹啉衍生物 | |
| RU2015124954A (ru) | Фармацевтические комбинации | |
| ES2855075T3 (es) | Combinación de ceritinib con un inhibidor de EGFR | |
| RU2017143182A (ru) | Способы и композиции для ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| EP4615869A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| JP2007537184A (ja) | 抗血小板剤に対する耐性を治療するためのジピリダモールの使用 | |
| EP3458064A1 (en) | Anticancer combination therapy | |
| CA3113408A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
| CA3056878C (en) | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |